Spots Global Cancer Trial Database for mapk
Every month we try and update this database with for mapk cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | NCT04959981 | Advanced Non-sq... | ERAS-007 ERAS-601 Osimertinib Sotorasib | 18 Years - 99 Years | Erasca, Inc. | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | NCT04959981 | Advanced Non-sq... | ERAS-007 ERAS-601 Osimertinib Sotorasib | 18 Years - 99 Years | Erasca, Inc. | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies | NCT05279859 | Acute Myeloid L... | ERAS-007 ERAS-601 Gilteritinib | 18 Years - 99 Years | Erasca, Inc. | |
| A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors | NCT05538130 | Melanoma Glioma Thyroid Cancer Non-Small Cell ... Malignant Neopl... Brain Neoplasms Colorectal Canc... | PF-07799544 PF-07799933 encorafenib | 16 Years - | Pfizer | |
| A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | NCT02857270 | Advanced Cancer Metastatic Mela... Metastatic Non-... Colorectal Canc... | LY3214996 Midazolam Abemaciclib Nab-paclitaxel Gemcitabine Encorafenib Cetuximab | 18 Years - | Eli Lilly and Company | |
| Study of ASTX029 in Subjects With Advanced Solid Tumors | NCT03520075 | Solid Tumor, Ad... | ASTX029 | 18 Years - | Astex Pharmaceuticals, Inc. | |
| A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers. | NCT02711345 | Ovarian Neoplas... Non-Small-Cell ... Melanoma Other Solid Tum... | LTT462 | 12 Years - | Novartis | |
| A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | NCT02857270 | Advanced Cancer Metastatic Mela... Metastatic Non-... Colorectal Canc... | LY3214996 Midazolam Abemaciclib Nab-paclitaxel Gemcitabine Encorafenib Cetuximab | 18 Years - | Eli Lilly and Company | |
| A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors | NCT05538130 | Melanoma Glioma Thyroid Cancer Non-Small Cell ... Malignant Neopl... Brain Neoplasms Colorectal Canc... | PF-07799544 PF-07799933 encorafenib | 16 Years - | Pfizer | |
| Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) | NCT04485559 | Recurrent World... Low-grade Gliom... High Grade Glio... | Everolimus Trametinib | 1 Year - 25 Years | University of California, San Francisco | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies | NCT05279859 | Acute Myeloid L... | ERAS-007 ERAS-601 Gilteritinib | 18 Years - 99 Years | Erasca, Inc. | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | NCT04959981 | Advanced Non-sq... | ERAS-007 ERAS-601 Osimertinib Sotorasib | 18 Years - 99 Years | Erasca, Inc. | |
| Study of ASTX029 in Subjects With Advanced Solid Tumors | NCT03520075 | Solid Tumor, Ad... | ASTX029 | 18 Years - | Astex Pharmaceuticals, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
